We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Despite overall industry support for the FDA’s development of a voluntary Quality Management Maturity (QMM) program for establishments manufacturing drugs, stakeholders raised concerns about a lack of details and the level of transparency of report findings. Read More
The Biden Administration wants to investigate how private equity and other corporations’ increasing power and control of the health care system is affecting Americans. Read More
By listening to the experiences and concerns of patients with rare diseases, the FDA can get a better picture of the most troublesome symptoms. Read More
The FDA’s guidance on showing effectiveness through a single trial plus confirmatory evidence is off to a good start in offering direction on leveraging real-world data (RWD), but providing more specifics would be highly beneficial, industry comments say as comments close on the agency’s draft guidance. Read More
Checkpoint Therapeutics announced that the FDA has issued a complete response letter (CRL) for its cosibelimab BLA based on an inspection of the company’s third-party manufacturer, with no issues cited on the approvability of the drug itself. Read More
The FDA has released a revised Manual of Policies and Procedures (MAPP) on ANDA labeling revisions to reflect certain changes mandated by lawmakers late last year. Read More
An uptick in drug prices contributed to an increase of 8.4 percent in retail prescription drug spending in 2022, according to a recent CMS report. Read More
The FDA has announced a new Genetic Metabolic Diseases Advisory Committee (GeMDAC) to help the agency explore the complex issues related to genetic metabolic disease drug development. Read More